BioMarin Pharmaceuticals
BMRN
531 hedge funds and large institutions have $13.5B invested in BioMarin Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 78 funds opening new positions, 182 increasing their positions, 186 reducing their positions, and 82 closing their positions.
2% less repeat investments, than reductions
Existing positions increased: 182 | Existing positions reduced: 186
5% less first-time investments, than exits
New positions opened: 78 | Existing positions closed: 82
1% less funds holding
Funds holding: 539 → 531 (-8)
2.5% less ownership
Funds ownership: 100.54% → 98.04% (-2.5%)
16% less capital invested
Capital invested by funds: $16B → $13.5B (-$2.53B)
29% less funds holding in top 10
Funds holding in top 10: 7 → 5 (-2)
31% less call options, than puts
Call options by funds: $134M | Put options by funds: $195M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dodge & Cox
San Francisco,
California
|
+$168M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
+$153M |
| 3 |
Parnassus Investments
San Francisco,
California
|
+$95.2M |
| 4 |
Norges Bank
Oslo,
Norway
|
+$60.8M |
| 5 |
MNG
Manning & Napier Group
Fairport,
New York
|
+$50.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$111M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$87.1M |
| 3 |
ClearBridge Investments
New York
|
-$83.2M |
| 4 |
BlackRock
New York
|
-$63.7M |
| 5 |
Janus Henderson Group
London,
|
-$56.6M |
BMRN Hedge Fund Activity: Q1 2021 in Review
531 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q1 2021, worth a combined $13.5B — down 16% from $16B a quarter earlier.
Sellers outnumbered buyers: 82 funds closed out of BMRN and 78 opened new positions — a net loss of 4 holders — while 186 trimmed existing stakes and 182 added.
The largest buyer was Dodge & Cox, adding an estimated $168M. The largest seller was Citadel Advisors, cutting an estimated $111M.
- 531 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q1 2021, down from 539 in Q4 2020.
- Funds reported $13.5B of BioMarin Pharmaceuticals stock for Q1 2021, down 16% quarter-over-quarter.
- 78 funds opened new BioMarin Pharmaceuticals positions in Q1 2021 and 82 closed out, a net change of -4 holders.
- The largest BioMarin Pharmaceuticals buyer in Q1 2021 was Dodge & Cox, an estimated $168M added.
- The largest BioMarin Pharmaceuticals seller in Q1 2021 was Citadel Advisors, an estimated $111M sold.
Based on aggregated 13F filings for Q1 2021.